| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | EGFR | Synonyms | ERBB, ERBB1, ERRP, HER1, NISBD2, PIG61, mENA | Type of gene | protein-coding |
| Chromosome | 7 | Map location | 7p11.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | epidermal growth factor receptor | ||||
| GTO ID | GTC3829 |
| Trial ID | NCT06343376 |
| Disease | Chronic Lymphocytic Leukemia | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma | High Grade B-Cell Lymphoma | Mantle Cell Lymphoma |
| Altered gene | CD19|IL-12|EGFR |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | EGFRt/19-28z/IL-12 CAR T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase I Trial of CD19-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells Genetically Engineered to Secrete Interleukin 12 (IL-12) and With a Truncated Human Epidermal Growth Factor Receptor (EGFRt) in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies |
| Year | 2024 |
| Country | United States |
| Company sponsor | Roswell Park Cancer Institute |
| Other ID(s) | I-3641523|NCI-2024-01818|I-3641523 |
| Cohort 1 | |||||||||
|
|||||||||